Design Therapeutics (DSGN) Competitors $6.44 -0.68 (-9.55%) As of 09:43 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock DSGN vs. STOK, SNDX, AVDL, EVO, ORIC, XERS, JANX, LENZ, ATAI, and NUVBShould you be buying Design Therapeutics stock or one of its competitors? The main competitors of Design Therapeutics include Stoke Therapeutics (STOK), Syndax Pharmaceuticals (SNDX), Avadel Pharmaceuticals (AVDL), Evotec (EVO), Oric Pharmaceuticals (ORIC), Xeris Biopharma (XERS), Janux Therapeutics (JANX), LENZ Therapeutics (LENZ), atai Life Sciences (ATAI), and Nuvation Bio (NUVB). These companies are all part of the "pharmaceutical products" industry. Design Therapeutics vs. Its Competitors Stoke Therapeutics Syndax Pharmaceuticals Avadel Pharmaceuticals Evotec Oric Pharmaceuticals Xeris Biopharma Janux Therapeutics LENZ Therapeutics atai Life Sciences Nuvation Bio Design Therapeutics (NASDAQ:DSGN) and Stoke Therapeutics (NASDAQ:STOK) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, profitability, institutional ownership, media sentiment, earnings, dividends, risk and analyst recommendations. Do analysts rate DSGN or STOK? Stoke Therapeutics has a consensus price target of $27.43, suggesting a potential downside of 8.74%. Given Stoke Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Stoke Therapeutics is more favorable than Design Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Design Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00Stoke Therapeutics 1 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 2.89 Is DSGN or STOK more profitable? Stoke Therapeutics has a net margin of 26.25% compared to Design Therapeutics' net margin of 0.00%. Stoke Therapeutics' return on equity of 18.32% beat Design Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Design TherapeuticsN/A -27.15% -26.07% Stoke Therapeutics 26.25%18.32%15.48% Do institutionals & insiders have more ownership in DSGN or STOK? 56.6% of Design Therapeutics shares are held by institutional investors. 23.5% of Design Therapeutics shares are held by insiders. Comparatively, 9.5% of Stoke Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Does the media favor DSGN or STOK? In the previous week, Stoke Therapeutics had 28 more articles in the media than Design Therapeutics. MarketBeat recorded 31 mentions for Stoke Therapeutics and 3 mentions for Design Therapeutics. Design Therapeutics' average media sentiment score of 0.83 beat Stoke Therapeutics' score of 0.40 indicating that Design Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Design Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Stoke Therapeutics 7 Very Positive mention(s) 6 Positive mention(s) 9 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more volatility & risk, DSGN or STOK? Design Therapeutics has a beta of 1.68, indicating that its stock price is 68% more volatile than the S&P 500. Comparatively, Stoke Therapeutics has a beta of 1.24, indicating that its stock price is 24% more volatile than the S&P 500. Which has better earnings and valuation, DSGN or STOK? Design Therapeutics has higher earnings, but lower revenue than Stoke Therapeutics. Design Therapeutics is trading at a lower price-to-earnings ratio than Stoke Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioDesign TherapeuticsN/AN/A-$49.59M-$1.12-5.75Stoke Therapeutics$199.89M8.24-$88.98M$0.8535.36 SummaryStoke Therapeutics beats Design Therapeutics on 11 of the 16 factors compared between the two stocks. Get Design Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for DSGN and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding DSGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DSGN vs. The Competition Export to ExcelMetricDesign TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$371.49M$3.33B$6.05B$10.24BDividend YieldN/A2.31%5.73%4.78%P/E Ratio-5.8222.2586.3326.55Price / SalesN/A417.09600.12186.81Price / CashN/A44.9825.7330.17Price / Book1.5010.2112.866.52Net Income-$49.59M-$52.40M$3.31B$276.31M7 Day Performance1.42%0.20%-0.74%-2.92%1 Month Performance6.80%13.49%8.31%4.14%1 Year Performance28.80%27.29%79.14%30.13% Design Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DSGNDesign Therapeutics0.1956 of 5 stars$6.44-9.6%N/A+35.0%$371.49MN/A-5.8240Positive NewsHigh Trading VolumeSTOKStoke Therapeutics2.9494 of 5 stars$26.77-0.2%$25.57-4.5%+155.0%$1.46B$199.89M31.41100Analyst ForecastInsider TradeSNDXSyndax Pharmaceuticals3.5995 of 5 stars$16.39-0.1%$39.22+139.3%-16.0%$1.41B$23.68M-4.22110AVDLAvadel Pharmaceuticals2.8087 of 5 stars$14.42-0.8%$20.86+44.6%+6.7%$1.40B$169.12M-480.7770EVOEvotec2.176 of 5 stars$3.94-1.4%$7.00+77.9%+23.2%$1.40B$777.33M0.004,827ORICOric Pharmaceuticals4.1456 of 5 stars$14.16-1.7%$17.29+22.0%+46.6%$1.37BN/A-7.4980Gap UpXERSXeris Biopharma2.7392 of 5 stars$8.35+2.6%$7.08-15.1%+174.6%$1.35B$246.03M-39.78290JANXJanux Therapeutics2.5567 of 5 stars$22.44-1.4%$78.31+249.0%-46.5%$1.35B$10.59M-12.4530LENZLENZ Therapeutics1.7159 of 5 stars$46.63+1.1%$49.60+6.4%+57.0%$1.33BN/A-24.61110Analyst ForecastATAIatai Life Sciences2.9793 of 5 stars$5.55+1.4%$11.25+102.9%+363.6%$1.30B$310K-8.0580Analyst ForecastNUVBNuvation Bio2.7735 of 5 stars$3.65-3.3%$7.86+115.6%+64.3%$1.25B$7.87M-5.7960 Related Companies and Tools Related Companies STOK Alternatives SNDX Alternatives AVDL Alternatives EVO Alternatives ORIC Alternatives XERS Alternatives JANX Alternatives LENZ Alternatives ATAI Alternatives NUVB Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:DSGN) was last updated on 10/13/2025 by MarketBeat.com Staff From Our PartnersURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | Sponsored2013 miner reveals his trading systemWhile everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | Sponsored$3,600 gold is nice ... but here’s what most gold bugs are missingGold just surged past $3,600, but Weiss Ratings expert Sean Brodrick says the real upside is in select gold st...Weiss Ratings | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Design Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Design Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
